Skip to main content
SpringerLink
Log in

Viral Hepatitis in the Compromised Host

  • Chapter
Clinical Approach to Infection in the Compromised Host

  • 44 Accesses

Abstract

Four categories of viral hepatitis have been recognized: hepatitis A, hepatitis B, non-A, non-B hepatitis, and hepatitis B-associated delta hepatitis. Although all four have the potential to produce similar illnesses, clinical severity and outcome as well as the contribution of immunologic mechanisms to the clinical expression of infection and illness appear to differ among the various types. Observations of viral hepatitis in immunosuppressed persons have taught us important lessons about the biology of these viral agents, on the one hand, and about the approach to immunologically compromised patients with hepatitis, on the other. Unlike susceptibility of immunosuppressed persons to opportunistic infections, susceptibility to viral hepatitis per se is not increased in the immunosuppressed; however, because patients with immunologic derangements are very likely to require transfusions of blood products, the frequency of viral hepatitis in this group of patients is increased.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Szmuness W, Purcell RH, Dienstag JL, et al: Antibody to hepatitis A antigen in institutionalized mentally retarded patients. JAMA 237:1702–1705, 1977.

    Article  PubMed  CAS  Google Scholar 

  2. Szmuness W, Dienstag JL, Purcell RH, et al: Hepatitis type A and hemodialysis: A seroepidemiologic study in 15 U.S. centers. Ann Intern Med 87:8–12, 1977.

    PubMed  CAS  Google Scholar 

  3. Rizzetto M: The delta agent. Hepatology 3:729–737, 1983.

    Article  PubMed  CAS  Google Scholar 

  4. Popper H, Thung SN, Gerber MA, et al: Histologie studies of severe delta agent infection in Venezuelan Indians. Hepatology 3:906–912, 1983.

    Article  PubMed  CAS  Google Scholar 

  5. Friedman LS, Dienstag JL: The disease and its pathogenesis. In Gerety RJ (ed): Hepatitis A, Academic, Orlando, Florida, 1984, pp. 55–79.

    Google Scholar 

  6. Dienstag JL, Bhan AK, Klingenstein RJ, et al: Immu-nopathogenesis of liver disease associated with hepatitis B. In Szmuness W, Alter HJ, Maynard JE (eds): Viral Hepatitis-1981 International Symposium, Franklin Institute, Philadelphia, 1982, pp. 221–236.

    Google Scholar 

  7. Dienstag JL: Immunologic mechanisms in chronic viral hepatitis. In Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. Grune & Stratton, Orlando, Florida, 1984, pp. 135–166.

    Google Scholar 

  8. Blumberg BS, Sutnick AI, London WT: Australia antigen as a hepatitis virus: Variation in host response. Am J Med 48:1–8, 1970.

    Article  PubMed  CAS  Google Scholar 

  9. Blumberg BS, Gerstley BJS, Hungerford DA, et al: A serum antigen (Australia antigen) in Down’s syndrome, leukemia and hepatitis. Ann Intern Med 66:924–931, 1967.

    PubMed  CAS  Google Scholar 

  10. Blumberg BS, Sutnick AI, London WT: Hepatitis and leukemia: Their relation to Australia antigen. Bull NY Acad Med 44:1566–1586, 1968.

    CAS  Google Scholar 

  11. Szmuness W, Harley EJ, Ikram H, et al: Sociodemographic aspects of the epidemiology of hepatitis B. In Vyas GN, Cohen SN, Schmid R (eds): Viral Hepatitis. Franklin Institute, Philadelphia, 1978, pp. 297–320.

    Google Scholar 

  12. Markenson JA, Gerety RJ, Hoofnagle JH, et al: Effects of cyclophosphamide on hepatitis B virus infection and challenge in chimpanzees. J Infect Dis 131:79–87, 1975.

    Article  PubMed  CAS  Google Scholar 

  13. Galbraith RM, Eddieston ALWF, Williams R, et al: Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2:528–530, 1975.

    Article  PubMed  CAS  Google Scholar 

  14. Sagnelli E, Manzillo G, Maio G, et al: Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 2:395–397, 1980.

    Article  PubMed  CAS  Google Scholar 

  15. Scullard GH, Smith CI, Merigan TC, et al: Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81:987–991, 1981.

    PubMed  CAS  Google Scholar 

  16. Villa E, Theodossi A, Portmann B, et al: Reactivation of hepatitis B virus infection in two patients: Immunofluorescence studies of liver tissue, Gastroenterology 80:1048–1053, 1981.

    PubMed  CAS  Google Scholar 

  17. Reed WD, Eddleston ALWF, Cullens H, et al: Infusion of hepatitis B antibody in antigen-positive active chronic hepatitis. Lancet 2:1347–1451, 1975.

    Google Scholar 

  18. Kohler PF, Trembath J, Merrill DA, et al: Immunotherapy with antibody, lymphocytes and transfer factor in chronic hepatitis B. Clin ImmunolImmunopathol 2:465–471, 1974.

    Article  Google Scholar 

  19. Thomas HC, Chadwick RG, Jain S, et al: Levamisole therapy for HB s antigen positive chronic liver disease Gastroenterology 73:A52, 1977 (abst.).

    Google Scholar 

  20. Jain, S, Thomas HC, Sherlock S: Transfer factor in the attempted treatment of patients with HBsAg-positive chronic liver disease. Clin Exp Immunol 30:10–15, 1977.

    PubMed  CAS  Google Scholar 

  21. Good RA, Page AR: Fatal complications of virus hepatitis in two patients with agammaglobulinemia. Am J Med 29:804–810, 1960.

    Article  PubMed  CAS  Google Scholar 

  22. Mondelli M, Mieli Vergani G, Alberti A, et al: Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: Evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129:2773–2778, 1982.

    PubMed  CAS  Google Scholar 

  23. Naumov NV, Mondelli M, Alexander GJM, et al: Relationship between expression of hepatitis B virus antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic hepatitis B virus infection. Hepatology 4:63–68, 1984.

    Article  PubMed  CAS  Google Scholar 

  24. Ceuppens JL, Stevens E, Fevery J, et al: Complete recovery from hepatitis B and associated hemolysis in a patient with underlying T-cell deficiency. Gastroenterology 86:937–940, 1984.

    PubMed  CAS  Google Scholar 

  25. Romet-Lemonne JL, McLane MF, Elfassi E, et al: Hepatitis B virus infection in cultured human lymphoblastoid cells. Science 221:667–669, 1983.

    Article  PubMed  CAS  Google Scholar 

  26. Dienstag JL: Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 85:439–462, 1983.

    PubMed  CAS  Google Scholar 

  27. Dienstag JL: Non-A, non-B hepatitis. II. Experimental transmission, putative virus agents and markers, and prevention. Gastroenterology 85:743–768, 1983.

    PubMed  CAS  Google Scholar 

  28. Blumberg BS, Alter HJ, Visnich S: A “new” antigen in leukemia sera. JAMA 191:541–546, 1965.

    Article  PubMed  CAS  Google Scholar 

  29. Goldblum SE, Reed WP: Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 93:597–613, 1980.

    PubMed  CAS  Google Scholar 

  30. Agarwal SS, Blumberg BS, Gerstley BS, et al: DNA polymerase activity as an index of lymphocyte stimulation: Studies in Down’s syndrome. J Clin Invest 49:161–169, 1970.

    Article  PubMed  CAS  Google Scholar 

  31. Boughton CR, Hawkes RA, Schroeter DR, et al: The epidemiology of hepatitis B in a residential institution for the mentally retarded. Aust NZ J Med 6:521–529, 1976.

    Article  CAS  Google Scholar 

  32. Hawkes RA, Boughton CR, Schroeter DR, et al: Hepatitis B infection in institutionalized Down’s syndrome inmates: A longitudinal study with five hepatitis B virus markers. Clin Exp Immunol 40:478–486, 1980.

    PubMed  CAS  Google Scholar 

  33. Madden DL, Dietzman DE, Matthew EB, et al: Epidemiology of hepatitis B virus in an institution for mentally retarded persons. Am J Ment Defic 80:369–375, 1976.

    PubMed  CAS  Google Scholar 

  34. Chaudhary RK, Perry E, Cleary TE: Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. Am J Epidemiol 105:123–126, 1977.

    PubMed  CAS  Google Scholar 

  35. Szmuness W, Pick R, Prince AM: The serum hepatitis virus specific antigen (SH): A preliminary report of epidemiologic studies in an institution for the mentally retarded. Am J Epidemiol 92:51–61, 1970.

    PubMed  CAS  Google Scholar 

  36. Hollingsworth DR, Hollingsworth JW, Roeckel I, et al: Immunologic reactions and Australia antigenemia in Down’s syndrome. J Chron Dis 27:483–490, 1974.

    Article  PubMed  CAS  Google Scholar 

  37. Szmuness W, Neurath AR, Stevens CE; et al: Prevalence of hepatitis B “e” antigen and its antibody in various HBsAg carrier populations. Am J Epidemiol 113:113–121, 1981.

    PubMed  CAS  Google Scholar 

  38. Garibaldi RA, Forrest JN, Bryan JA, et al: Hemodialysis-associated hepatitis. JAMA 225:384–389, 1973.

    Article  PubMed  CAS  Google Scholar 

  39. Snydman DR, Bryan JA, Hanson B: Hemodialysis-associ-ated hepatitis in the United States—1972. J Infect Dis 132:109–113, 1975.

    Article  PubMed  CAS  Google Scholar 

  40. Szmuness W, Prince AM, Grady GF, et al: Hepatitis B infection: A point-prevalence study in 15 US hemodialysis centers. JAMA 227:901–906, 1974.

    Article  PubMed  CAS  Google Scholar 

  41. Centers for Disease Control: Hepatitis—Control measures for hepatitis B in dialysis centers. Viral hepatitis investigations and control series. U.S. Department of Health, Education and Welfare, Phoenix, November 1977, pp. 1–9.

    Google Scholar 

  42. Szmuness W: Large-scale efficacy trials of hepatitis B vaccines in the USA: Baseline data and protocols: J Med Virol 4:327–340, 1979.

    Article  PubMed  CAS  Google Scholar 

  43. Sengar DPS, Rashid A, McLeish WA, et al: Hepatitis B surface antigen (HBsAg) infection in a hemodialysis unit. II. Factors affecting host immune response to HBsAg. Can Med Assoc J 113:945–948, 1975.

    PubMed  CAS  Google Scholar 

  44. London WT, Drew JS, Lustbader ED, et al: Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int 12:51–58, 1977.

    Article  PubMed  CAS  Google Scholar 

  45. Snydman DS, Bregman D, Bryan JA: Hemodialysis-associ-ated hepatitis in the United States, 1974. J Infect Dis 135:687–691, 1977.

    Article  Google Scholar 

  46. Ribot S, Rothstein M, Goldblat M, et al: Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 139:178–180. 1979.

    Article  PubMed  CAS  Google Scholar 

  47. Gahl GM, Hess G, Arnold W, et al: Hepatitis B virus markers in 97 long-term hemodialysis patients. Nephron 24:58–63, 1979.

    Article  PubMed  CAS  Google Scholar 

  48. Beorchia S, Trepo C, Betuel H, et al: Interest of HBeAg in the study of immunogenetic factors influencing HBV infection in hemodialysed and kidney transplanted patients. In Touraine JL, Traeger J, Betuel H, et al (eds): Transplantation and Clinical Immunology. Vol 10. Excerpta Medica, Amsterdam, 1979, pp. 44–49.

    Google Scholar 

  49. Snydman DR, Bryan JA, Macon EJ, et al: Hemodialysis-associated hepatitis: Report of an epidemic with further evidence on mechanisms of transmission. Am J Epidemiol 104:563–570, 1976.

    PubMed  CAS  Google Scholar 

  50. Garibaldi RA, Hatch FE, Bisno AL, et al: Nonparenteral serum hepatitis: Report of an outbreak. JAMA 220:963–966, 1972.

    Article  PubMed  CAS  Google Scholar 

  51. Coughlin GP, Van Deth AG, Disney APS, et al: Liver disease and the e antigen in HBsAg carriers with chronic renal failure. Gut 21:118–122, 1980.

    Article  PubMed  CAS  Google Scholar 

  52. Degott C, Degos F, Jungers P, et al: Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver 3:377–384, 1983.

    PubMed  CAS  Google Scholar 

  53. Jüngers P, Naret C, Degott C, et al: Histological and immunological survey of chronic active hepatitis in 650 hemo-dialyzed patients. In Touraine JL, Traeger J, Betuel H, et al (eds): Transplantation and Clinical Immunology. Vol. 10. Excerpta Medica, 1979, pp. 38–43.

    Google Scholar 

  54. Galbraith RM, Dienstag JL, Purcell RH, et al: Non-A non-B hepatitis associated with chronic liver disease in a hemodialysis unit. Lancet 1:951–953, 1979.

    Article  PubMed  CAS  Google Scholar 

  55. Galbraith RM, Portmann B, Eddleston ALWF, et al: Chronic liver disease developing after outbreak of HBsAg-nega-tive hepatitis in haemodialysis unit. Lancet 2:886–890, 1975.

    Article  PubMed  CAS  Google Scholar 

  56. Marmion BP, Burrell CJ, Tonkin RW, et al: Dialysis-associated hepatitis in Edinburgh, 1969–1978. Rev Infect Dis 4:619–637, 1982.

    Article  PubMed  CAS  Google Scholar 

  57. Coursaget P, Maupas P, Dubois F, et al: Hepatites non-A, non-B chez six malades hemodialyses. Nouv Presse Med 7:3515–3519, 1978.

    Google Scholar 

  58. Mery JP, Simon N, Courouce AM: Hepatite non-A, non-B chez les hemodialyses chroniques: 5 observations. Nouv Presse Med 8:3973, 1979.

    CAS  Google Scholar 

  59. Koretz RL, Stone O, Brezina M, et al: Chronic hepatitis in the dialysis unit: Etiologic considerations. Gastroenterology 78:1198, 1980 (abst).

    Google Scholar 

  60. Dienstag JL, Stevens CE, Szmuness W: The epidemiology of non-A, non-B hepatitis: Emerging patterns. In Gerety JR (ed): Non-A, non-B Hepatitis. Academic, New York, 1981, pp. 119–137.

    Google Scholar 

  61. Simon N, Mery JP, Trepo C, et al: A non-A, non-B hepatitis epidemic in a HB antigen-free hemodialysis unit: Demonstration of serological markers of non-A, non-B virus, Proc Eur Dial Transplant Assoc 17:173–178, 1980.

    PubMed  CAS  Google Scholar 

  62. Avram MM, Feinfeld DA, Gan AC: Non-A, non-B hepatitis: A new syndrome in uraemic patients. Proc Eur Dial Transplant Assoc 16:141–147, 1979.

    PubMed  CAS  Google Scholar 

  63. Wolf JL, Perkins HA, Schreeder MT, et al: The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 91:412–413, 1979.

    PubMed  CAS  Google Scholar 

  64. Lutwick LI, SyWassink JM, Corry RJ, et al: The renal transplant as a source of hepatitis B virus (HBV). Clin Res 29:258A, 1981 (abst.).

    Google Scholar 

  65. Degos F, Degott C, Bedrossian J, et al: Is renal transplantation involved in post-transplantation liver disease? A prospective study. Transplantation 29:100–102, 1980.

    Article  PubMed  CAS  Google Scholar 

  66. Toussaint C, Thiry L, Kinnaert P, et al: Prognostic significance of hepatitis B antigenemia in kidney transplantation. Nephron 17:335–342, 1976.

    Article  PubMed  CAS  Google Scholar 

  67. Luby JP, Burnett W, Hull AR, et al: Relationship between cytomegalovirus and hepatic function abnormalities in the period after renal transplant. J Infect Dis 129:511–518, 1974.

    Article  PubMed  CAS  Google Scholar 

  68. Kaiser L, Kelly TJ, Patterson MJ, et al: Hepatitis B surface antigen in urine of renal transplant recipients. Ann Intern Med 94:783–784, 1981.

    PubMed  CAS  Google Scholar 

  69. Mayor GH, Kelly TJ, Hourani MR, et al: Intermittent hepatitis B surface antigenuria in a renal transplant recipient. Am J Med 68:305–307, 1980.

    Article  PubMed  CAS  Google Scholar 

  70. Nagington J, Cossart YE, Cohen BJ: Reactivation of hepatitis B after transplantation operations. Lancet 1:558–560, 1977.

    Article  PubMed  CAS  Google Scholar 

  71. Dusheiko G, Song E, Bowyer S, et al: Natural history of hepatitis B virus infection in renal transplant recipients—A fifteen-year follow-up. Hepatology 3:330–336, 1983.

    Article  PubMed  CAS  Google Scholar 

  72. London WT, Drew JS, Blumberg BS, et al: Association of graft survival with host response to hepatitis B infection in patients with kidney transplants. N Engl J Med 296:241–244, 1977.

    Article  PubMed  CAS  Google Scholar 

  73. London WT, Jarvinen H, Jasko L, et al: Hepatitis B virus infection in kidney transplant recipients. In Bianchi L, Gerok W, Sickinger K, et al (eds): Virus and the Liver. MTP Press, Lancaster, 1980, pp. 267–276.

    Google Scholar 

  74. Jarvinen H, Shofer FS, Burke JF, et al: Antibody to hepatitis B surface antigen and kidney graft survival. Transplant Proc 15:1094–1098, 1983.

    Google Scholar 

  75. Toussaint C, Cappel R, Vereerstraeten P, et al: Graft survival and response to hepatitis-B virus in kidney recipients. Transplant Proc 11:89–92, 1979.

    PubMed  CAS  Google Scholar 

  76. Pirson Y, Alexandre GPJ, van Ypersele de Strihou C: Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 296:194–196, 1977.

    Article  PubMed  CAS  Google Scholar 

  77. Hillis WD, Hillis A, Walker WG: Hepatitis B surface antigenemia in renal transplant recipients: Increased mortality risk. JAMA 242:329–332, 1979.

    Article  PubMed  CAS  Google Scholar 

  78. Chatterjee SN, Payne JE, Bischeil MD, et al: Successful renal transplantation in patients positive for hepatitis B antigen. N Engl J Med 291:62–65, 1974.

    Article  PubMed  CAS  Google Scholar 

  79. Berne TV, Fitzgibbons TJ, Silberman H: The effect of hepatitis B antigenemia on long-term success and hepatic disease in renal transplantation. Transplantation 24:412–415, 1977.

    Article  PubMed  CAS  Google Scholar 

  80. Fine RN, Malekzadeh MH, Pennisi AJ, et al: HBs antigenemia in renal allograft recipients. Ann Surg 185:411–416, 1977.

    Article  PubMed  CAS  Google Scholar 

  81. Ponticelli C, De Vecchi A, Cantaluppi A, et al : Hepatitis and renal transplants. (Letter.) N Engl J Med 296:1170, 1977.

    Google Scholar 

  82. Rashid A, Sengar D, Couture RR et al: Hepatitis and renal transplants. (Letter.) N Engl J Med 296:1170–1171, 1977.

    Google Scholar 

  83. Hillis WD, Hillis A, Bias WB. et al: Association of hepatitis B surface antigenemia with HLA locus B specificities. N N Engl J Med 296:1310–1314, 1977.

    Article  CAS  Google Scholar 

  84. Opelz G, Terasaki PI: Graft survival rates and HLA antigen frequencies in renal cadaver transplant recipients with hepatitis B antigenemia. Transplantation 25:159–161, 1978.

    Article  PubMed  CAS  Google Scholar 

  85. Parfrey PS, Forbes RDC, Hutchinson TA, et al: The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 37:461–466, 1984.

    Article  PubMed  CAS  Google Scholar 

  86. Schröter GPJ, Weill R III, Penn I, et al: Hepatocellular carcinoma associated with chronic hepatitis B virus infection after kidney transplantation. (Letter.) Lancet 2:381–382, 1982.

    Article  PubMed  Google Scholar 

  87. Anuras S, Piros J, Bonney WW, et al: Liver disease in renal transplant recipients. Arch Intern Med 137:42–48, 1977.

    Article  PubMed  CAS  Google Scholar 

  88. Strom TB: Hepatitis B, transfusions, and renal transplantation—five years later. (Editorial.) N Engl J Med 307:1141–1142, 1982.

    Article  PubMed  CAS  Google Scholar 

  89. Berne TV, Chatterjee SN, Craig JR, et al: Hepatic dysfunction in recipients of renal allografts. Surg Gynecol Obstet 141:171–175, 1975.

    PubMed  CAS  Google Scholar 

  90. Mozes MF, Ascher NL, Balfour HHJ, et al: Jaundice after renal allotransplantation. Ann Surg 188:783–790, 1978.

    Article  PubMed  CAS  Google Scholar 

  91. Ware AJ, Luby JP, Hollinger B, et al: Etiology of liver disease in renal-transplant patients. Ann Intern Med 91:364–371, 1979.

    PubMed  CAS  Google Scholar 

  92. Alvarez V, Plaza JJ, Carreno V, et al: Viral infections and liver damage in renal transplant patients. Gastroenterology 79:1001, 1980 (abst.).

    Google Scholar 

  93. Fennell RS III, Andres JM, Pfaff WW, et al: Liver dysfunction in children and adolescents during hemodialysis and after renal transplantation. Pediatrics 67:855–861, 1981.

    PubMed  Google Scholar 

  94. LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, et al: Impact of hepatitis on renal transplantation. Transplantation 32:504–507, 1981.

    Article  PubMed  CAS  Google Scholar 

  95. Alter HJ, Hoofnagle JH: Non-A, non-B: Observations on the first decade. In Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. Grune & Stratton, Orlando, 1984, pp. 345–354.

    Google Scholar 

  96. Wyke RJ, Williams R: Clinical aspects of non-A, non-B hepatitis infection. J Virol Methods 2:17–29, 1980.

    Article  PubMed  CAS  Google Scholar 

  97. Sutnick AI, London WT, Blumberg BS, et al: Australia antigen (a hepatitis associated antigen) in leukemia. J Natl Cancer Inst 44:1241–1249, 1970.

    PubMed  CAS  Google Scholar 

  98. Sutnick AI, Levine PH, London WT, et al: Frequency of Australia antigen in patients with leukemia in different countries. Lancet 1:1200–1202, 1971.

    Article  PubMed  CAS  Google Scholar 

  99. Grange MJ, Erlinger S, Teilletd F, et al: A possible relationship to treatment between hepatitis-associated antigen and chronic persistent hepatitis in Hodgkin’s disease. Gut 14:433–437, 1973.

    Article  PubMed  CAS  Google Scholar 

  100. Wands JR, Chura CM, Roll FJ, et al: Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lympho-proliferative disorders. Gastroenterology 68:105–112, 1975.

    PubMed  CAS  Google Scholar 

  101. Wands JR, Walker JA, Davis TT, et al: Hepatitis B in an oncology unit. N Engl J Med 291:1371–1375, 1974.

    Article  PubMed  CAS  Google Scholar 

  102. Schulman AN, Fagen ND, Brezina M, et al: HBe-antigen in the course and prognosis of hepatitis B infection: A prospective study. Gastroenterology 78:253–258, 1980.

    PubMed  CAS  Google Scholar 

  103. Trinchet JC, Beaugrand M, Hecht Y, et al: Hépatite fulminante à virus B survenue au cours d’un traitement immunodepresseur. Gastroenterol Clin Biol 4:59–62, 1980.

    PubMed  CAS  Google Scholar 

  104. Hoofhagle JH, Dusheiko GM, Schafer DF, et al: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447–449, 1982.

    Google Scholar 

  105. Vergani D, Locasciulli A, Masera G, et al: Histological evidence of hepatitis-B-virus infection with negative serology in children with acute leukemia who develop chronic liver disease. Lancet 1:361–364, 1982.

    Article  PubMed  CAS  Google Scholar 

  106. Wade JC, Gaffey M, Wiernik PH, et al: Hepatitis in patients with acute nonlymphocytic leukemia, Am J Med 75:413–422, 1983.

    Article  PubMed  CAS  Google Scholar 

  107. Locasciu Ui A, Santamaría M, Masera G, et al: Hepatitis B virus markers in children with acute leukemia: The effect of chemotherapy. J Med Virol 15:29–33, 1985.

    Article  Google Scholar 

  108. Cowan DH, Kouroupis GM, Leers W-D: Occurrence of hepatitis and hepatitis B surface antigen in adult patients with acute leukemia. Can Med Assoc J 112:693–697, 1975.

    PubMed  CAS  Google Scholar 

  109. Sauerbruch T, Frosner G, Theml H, et al: Hepatitis B-virus-marker und rotelnantikorper bei patienten mit hodgkin-, non-hodgkin-lymphomen und allgemein internistischen erkrankungen. Blut 40:259–266, 1980.

    Article  PubMed  CAS  Google Scholar 

  110. Tabor E, Gerety RJ, Mort M, et al: Prevalence of hepatitis B in a high risk setting: A serlogic study of patients and staff in a pediatric oncology unit. Pediatrics 61:711–715, 1978.

    PubMed  CAS  Google Scholar 

  111. Weitberg AB, Weitzman SA, Watkins E, et al: Immu-nogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy. J Clin Oncol 3:718–722, 1985.

    PubMed  CAS  Google Scholar 

  112. Schulman AN, Fagen ND, Ling CM, et al: Repeated type B hepatitis infections: Ten case studied prospectively. Gastroenterology 72:1182, 1977 (abst).

    Google Scholar 

  113. Lightdale CJ, Ikram H, Pinsky C: Primary hepatocellular carcinoma with hepatitis B antigenemia: Effects of chemotherapy. Cancer 46:1117–1122, 1980.

    Article  PubMed  CAS  Google Scholar 

  114. Steinberg SC, Alter HJ, Leventhal BG: The risk of hepatitis transmission to family contacts of leukemia patients. J Pediatr 87:753–757, 1975.

    Article  PubMed  CAS  Google Scholar 

  115. Wands JR: Subacute and chronic active hepatitis after withdrawal of chemotherapy. (Letter.) Lancet 2:979, 1975.

    Article  PubMed  CAS  Google Scholar 

  116. Thung SN, Gerber MA, Klion F, et al: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 145:1313–1314, 1985.

    Article  PubMed  CAS  Google Scholar 

  117. Malone W, Novak R: Outcome of hepatitis in children with acute leukemia. Am J Dis Child 134:584–587, 1980.

    PubMed  CAS  Google Scholar 

  118. Locasciu Ui A, Alberti A, Barbieri R, et al: Evidence of non-A, non-B hepatitis in children with acute leukemia and chronic liver disease. Am J Dis Child 173:354–356, 1983.

    Google Scholar 

  119. Barton JB, Conrad ME: Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med 90:188–190, 1979.

    PubMed  CAS  Google Scholar 

  120. Foon KA, Yale C, Clodfelter K, et al: Posttransfusion hepatitis in acute myelogenous leukemia: Effect on leukemia. JAMA 244:1806–1807, 1980.

    Article  PubMed  CAS  Google Scholar 

  121. Rotoli B, Formisano S, Martinelli V: Long-term survival in acute myelogenous leukemia complicated by chronic active hepatitis. (Letter.) N Engl J Med 307:1712–1713, 1982.

    PubMed  CAS  Google Scholar 

  122. Cacciola E, Giustolisi R: Acute myelogenous leukemia and hepatitis. (Letter.) Ann Intern Med 92:127–128, 1980.

    PubMed  CAS  Google Scholar 

  123. Brody SA, Russell WG, Krantz SB, et al: Beneficial effect of hepatitis in leukemic reticuloendotheliosis. Arch Intern Med 141:1080–1081, 1981.

    Article  PubMed  CAS  Google Scholar 

  124. Shepard KV, Levin B, Faintuch J, et al: Hepatitis as a beneficial prognostic factor in patients receiving intra-arterial chemotherapy for metastatic colorectal carcinoma. Clin Res 31:779A, 1983 (abst.).

    Google Scholar 

  125. Rosner F: Hepatitis and leukemia. (Letter.) Ann Intern Med 90:853, 1979.

    PubMed  CAS  Google Scholar 

  126. van den Ouweland FA, Holdrinet RSG, de Pauw BE, et al: Transaminase, hepatitis B, and prognosis in acute non-lymphoblastic leukemia. (Letter.) N Engl J Med 309:990, 1983.

    PubMed  Google Scholar 

  127. Julia A, Font L: Hepatitis and leukemia. (Letter.) Ann Intern Med 93:780, 1980.

    PubMed  CAS  Google Scholar 

  128. Carmichael GP, Zahradnik JM, Mover GH, et al: Adenovirus hepatitis in an immunosuppressed adult patient. Am J Clin Pathol 71:352–355, 1979.

    PubMed  Google Scholar 

  129. Katz ME, Cassileth PA: Hyperbilirubinemia during induction therapy of acute granulocytic leukemia. Cancer 40:1390–1392, 1977.

    Article  Google Scholar 

  130. Public Health Laboratory Service Survey: Hepatitis B in retreat from dialysis units in United Kingdom in 1973. Br Med J 1:1579–1581, 1976.

    Article  Google Scholar 

  131. Postic B, Schreiner DP, Hanchett JE, et al: Containment of hepatitis B virus infection in a hemodialysis unit. J Infect Dis 138:884–889, 1978.

    Article  PubMed  CAS  Google Scholar 

  132. Najem GR, Louria DB, Thind IS, et al: Control of hepatitis B infection: The role of surveiUance and an isolation hemodialysis center. JAMA 245:153–157, 1981.

    Article  PubMed  CAS  Google Scholar 

  133. Immunization Practices Advisory Committee: Recommendations for protection against viral hepatitis. MMWR 34:313–324, 329–335, 1985.

    Google Scholar 

  134. Stevens CE, Szmuness W, Goodman AI, et al: Hepatitis B vaccine: Immune response in hemodialysis patients. Lancet 2:1211–1213, 1980.

    Article  PubMed  CAS  Google Scholar 

  135. Stevens CE, Alter HJ, Taylor PE, et al: Hepatitis B vaccine in patients receiving hemodialysis: Immunogenicity and efficacy. N Engl J Med 311:496–501, 1984.

    Article  PubMed  CAS  Google Scholar 

  136. Grob PJ, Binswanger U, Zaruba K, et al: Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res 3:43–52, 1983.

    Article  PubMed  CAS  Google Scholar 

  137. Bergamini F, Zanetti AR, Ferroni P, et al: Immune response to hepatitis B vaccine in staff and patients in renal dialysis units. J Infect 7 (Suppl. l):35–40, 1983.

    Article  PubMed  Google Scholar 

  138. Crosnier J, Jungers P, Courouce A-M, et al: Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units. II. Haemodialysis patients. Lancet 2:797–800, 1981.

    Article  Google Scholar 

  139. Desmyter J, Colaert J, De Groot G, et al: Efficacy of heat-inactivated hepatitis B vaccine in hemodialysis patients and staff: Double-blind placebo-controlled trial. Lancet 2:1323–1327, 1983.

    Article  PubMed  CAS  Google Scholar 

  140. Desmyter J, Colaert J: Comparative immunogenicity of MSD, Pasteur and CLB hepatitis B vaccines in 245 hemodialysis patients (abst). In Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. Grune & Strat-ton, Orlando, 1984, pp. 709–710.

    Google Scholar 

  141. Jacobson IM, Jaffers G, Dienstag JL, et al: Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation 39:393–395, 1985.

    Article  PubMed  CAS  Google Scholar 

  142. Arnold W, Baumann W: Vaccination of children with malignant diseases with alum-adsorbed hepatitis B vaccine—Immunogenicity studies. Scand J Infect Dis 38(Suppl):33–36, 1983.

    CAS  Google Scholar 

  143. Dienstag JL, Werner BF, Polk BF, et al: Hepatitis B vaccine in health care personnel: Safety, immunogenicity, and indicators of efficacy. Ann Intern Med 101:34–40, 1984.

    PubMed  CAS  Google Scholar 

  144. Centers for Disease Control: Postexposure prophylaxis of hepatitis B: Recommendations of the Immunization Practices Advisory Committee. Ann Intern Med 101:351–354, 1984.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Unit, Medical Services, Massachusetts General Hospital; and Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02114, USA

    Jules L. Dienstag

Authors
  1. Jules L. Dienstag
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Infectious Disease and Transplantation Units, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA

    Robert H. Rubin M.D.

  2. Division of Infectious Diseases, Pacific Presbyterian Medical Center, Kuzell Institute for Arthritis and Infectious Diseases, San Francisco, California, USA

    Lowell S. Young M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Plenum Publishing Corporation

About this chapter

Cite this chapter

Dienstag, J.L. (1988). Viral Hepatitis in the Compromised Host. In: Rubin, R.H., Young, L.S. (eds) Clinical Approach to Infection in the Compromised Host. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6642-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6642-7_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4615-6644-1

  • Online ISBN: 978-1-4615-6642-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation